Equities

Coherus BioSciences Inc

Coherus BioSciences Inc

Actions
  • Price (EUR)1.01
  • Today's Change-0.032 / -3.07%
  • Shares traded0.00
  • 1 Year change-45.73%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments118192417
Total Receivables, Net261110123
Total Inventory633938
Prepaid expenses354124
Other current assets, total------
Total current assets476381602
Property, plant & equipment, net111416
Goodwill, net0.94--0.94
Intangibles, net715.932.62
Long term investments------
Note receivable - long term------
Other long term assets717957
Total assets630481679
LIABILITIES
Accounts payable351216
Accrued expenses293126148
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.721.190.74
Other current liabilities, total3.30----
Total current liabilities332139165
Total long term debt474472409
Total debt474474410
Deferred income tax1.10----
Minority interest------
Other liabilities, total167.107.50
Total liabilities823618582
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,3861,2041,148
Retained earnings (accumulated deficit)(1580)(1342)(1050)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.25)(0.25)(0.27)
Total equity(193)(137)98
Total liabilities & shareholders' equity630481679
Total common shares outstanding1127977
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.